Let’s be honest about how most of us learned to think about space. It was Captain Kirk, swaggering across the cosmos with a tricorder in one hand and, let’s just say, other priorities occupying the other, treating the final frontier like an interstellar singles bar with a Prime Directive he ignored roughly every other episode. Or it was Ripley, sweat-soaked and shotgun-loaded, learning that the universe’s idea of a welcome party involves something with acid for blood and a real talent for hide-and-seek in air ducts. Space, we were told, was either a playground for conquest or a nightmare factory. Sex, danger, repeat.
Nobody wrote the script where space spends its days quietly growing protein crystals for a Merck immunotherapy drug. And yet, here we are.
Turns out pharma has been sneaking payloads onto the International Space Station since the Space Shuttle days, when Merck and Bristol Myers Squibb figured out that zero gravity makes for better-behaved protein crystals — no convection, no sedimentation, just clean, orderly molecules that are easier to study. Once the ISS came online in 2000, this became a proper research pipeline: cancer formulations, muscle-wasting studies, and eventually Keytruda’s glow-up from a three-hour IV infusion to a quick subcutaneous shot, engineered in orbit and approved by the FDA in 2025 — the first drug to owe its formulation to a spacecraft.
The upside is real: bigger, purer crystals means better-designed drugs, cancer cells that grow 365 times faster in microgravity mean researchers can find drug targets in days instead of years, and lower-viscosity formulations mean patients get a quick jab instead of an afternoon hooked to an IV.
The downside is also real, and less cinematic than an alien bursting out of someone’s chest, but a headache nonetheless. Cosmic radiation degrades drugs faster than their Earth-bound twins. Astronaut biology — shifting fluids, atrophying muscles, a confused gut microbiome — makes dosing an educated guess rather than a science. Bacteria, annoyingly, become tougher and more drug-resistant up there. And every experiment costs a small fortune, somewhere between $250,000 and half a million dollars a pop, which is a steep price for “maybe better crystals.”
None of that is slowing anyone down. With the ISS set to retire around 2030, a new fleet of commercial stations — Axiom, Starlab, Orbital Reef, Haven-1 — is lining up to inherit the lab space, and companies like Varda and Redwire’s SpaceMD are already flying dozens of automated capsules for Eli Lilly and Bristol Myers Squibb without an astronaut in sight. Analysts expect the in-space manufacturing market to roughly triple to as much as $11 billion by the early 2030s, and Varda’s CEO isn’t shy about predicting nightly cargo drops of manufactured drugs within a decade.
Will there be growing pains? Sure — falling budgets and rising commercialization mean the un-sexy, non-profitable science (aging research, rare diseases) might get squeezed out in favor of whatever pays. But the trajectory is clear: space’s job description has quietly shifted from conquest and carnage to quality control.
So no, nobody’s chasing anyone across the galaxy up there. But somewhere above our heads, a very unglamorous batch of crystals is reshaping your next prescription — and pharma’s newest R&D wing has officially adopted the only mission statement that ever made sense for this whole endeavor: to infinity, and beyond.
Mike Auerbach
Pharma Group Editor-in-Chief
mauerbach@comparenetworks.com
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!